PF-00562271
Modify Date: 2024-01-03 11:55:24
PF-00562271 structure
|
Common Name | PF-00562271 | ||
|---|---|---|---|---|
| CAS Number | 939791-38-5 | Molecular Weight | 665.664 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C27H26F3N7O6S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PF-00562271PF-562271 (besylate) is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 kinase with IC50 of 1.5 nM and 13 nM, and has > 100-fold selectivity against other protein kinases, except for some CDKs. |
| Name | pf-562271 |
|---|---|
| Synonym | More Synonyms |
| Description | PF-562271 (besylate) is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 kinase with IC50 of 1.5 nM and 13 nM, and has > 100-fold selectivity against other protein kinases, except for some CDKs. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.5 nM (FAK), 13 nM (Pyk2) |
| In Vitro | PF-562,271 is a 30- to 120-nM (15.2 to 60.1 ng/mL) inhibitor of cdk2/E, cdk5/p35, cdk1/B, and cdk3/E in recombinant enzyme assays[1]. PF-562,271 blocks bFGF-stimulated blood vessel angiogenesis as performed in chicken chorioallantoic membrane assays[2]. Treatment of cells with PF-562,271 or knock-down of FAK by siRNA is observed to increase cell-cell adhesion strength[3]. |
| In Vivo | PF-562,271 (33 mg/kg, p.o.) inhibits FAK phosphorylation in tumors in a dose- and time-dependent manner in tumor-bearing mice. FAK phosphorylation inhibition relative to total blood concentration of PF-562,271 results in a calculated EC50 of 93 ng/mL. PF-562,271 (25 mg/kg, p.o.) induces apoptosis 2-fold greater in treated tumors compared with vehicle-treated control tumors on day 3[1]. PF-562,271 (33 mg/kg, p.o.) and dasatinib extensively inhibit the movement of tumor cells in the animals. Inhibition of FAK kinase activity following treatment with PF-562,271 results in altered E-cadherin dynamics in vivo[3]. |
| Kinase Assay | Briefly, purified-activated FAK kinase domain (amino acid 410-689) is reacted with 50 μM ATP and 10 μg per well of a random peptide polymer of Glu and Tyr, p(Glu/Tyr), in kinase buffer [50 mM HEPES (pH 7.5), 125 mM NaCl, and 48 mM MgCl2] for 15 min. Phosphorylation of p(Glu/Tyr) is challenged with serially diluted compound at 1/2-Log concentrations starting at a top concentration of 1 μM. Each concentration is tested in triplicate. Phosphorylation of p(Glu/Tyr) is detected with a general antiphospho-tyrosine (PY20) antibody followed by horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody. HRP substrate is added, and absorbance readings at 450 nm are obtained after addition of stop solution (2mol/LH2SO4). IC50 values are determined using the Hill-Slope Model. |
| Animal Admin | Exponentially growing cells are trypsinized and resuspended in sterile PBS and inoculated s.c. (1×106 cells per mouse in 200 μL) into the right flank of mice. Animals bearing tumors of appr 150 mm3 in size are divided into groups receiving either vehicle (5% Gelucire) or PF-562,271 (diluted in vehicle), and dosed by p.o. gavage. Animal body weight and tumor measurements are obtained every 2 d. Tumor volume (mm3) is measured with Vernier calipers and calculated. For all tumor growth inhibition experiments, 8 to 10 mice per dose group are used. |
| References |
| Molecular Formula | C27H26F3N7O6S2 |
|---|---|
| Molecular Weight | 665.664 |
| Exact Mass | 665.133789 |
| PSA | 200.34000 |
| LogP | 6.51540 |
| Storage condition | -20°C |
|
~%
PF-00562271 CAS#:939791-38-5 |
| Literature: Pfizer Inc. Patent: US2011/33441 A1, 2011 ; |
|
~%
PF-00562271 CAS#:939791-38-5 |
| Literature: Pfizer Inc. Patent: US2011/33441 A1, 2011 ; |
|
~%
PF-00562271 CAS#:939791-38-5 |
| Literature: Pfizer Inc. Patent: US2011/33441 A1, 2011 ; |
| Precursor 3 | |
|---|---|
| DownStream 0 | |
| N-methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethylpyrimidin-4-ylamino]methyl}pyridin-2-yl)methanesulfonamide monobesylate |
| RS0038s |
| N-Methyl-N-{3-[({2-[(2-oxo-2,3-dihydro-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl}amino)methyl]-2-pyridinyl}methanesulfonamide benzenesulfonate (1:1) |
| Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-N-methyl-, benzenesulfonate (1:1) |
| PF-562,271 |
| Methanesulfonamide,N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-N-methyl-,benzenesulfonate (1:1) |
| cc-23 |
| benzenesulfonic acid,N-methyl-N-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide |
| PF-562271 (besylate) |